
Opinion|Videos|April 8, 2024
Safety Profile of GVHD Treatment Options
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































